

DAFTAR PUSTAKA

- Abdel-Moneim, A., Aboud, A., Abdel-Gabaar, M., Zanaty, M.I., Ramadan, M., 2018. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4. *Hepatology International*. doi.org/10.1007/s12072-018-9868-8.
- Al-Khattiba, A., El-Nakeebc, A., Musab, N.I., Dousc, K.B.A., Aly, H., 2019. Noninvasive assessment of hepatic fibrosis regression in hepatitis C virus-infected patients treated with sofosbuvir-based therapy. *The Egyptian Journal of Internal Medicine* 31:556-562.
- Ali, O.M., Hussein, A.A., Kholef, E.F., Elsewify, W.A., 2020. Effect of sofosbuvir plus daclatasvir on virological response and liver function tests as a line of treatment for HCV related cirrhosis (a prospective cohort study). *Egyptian Liver Journal* 10:27.
- Asselah, T., Bie`che, I., Sabbagh, A., Bedossa, P., Moreau, R., Valla, D., *et al.*, 2009. Gene expression and hepatitis C virus infection. *Gut* 58:846-858.
- Bayupurnama, P. 2012. Tatalaksana Hepatitis B dan C Khronik dalam Praktik Klinik Sehari-hari. Yogyakarta: Nuha Medika.
- Besheer, T., El-Bendary, M., Elalfy, H., El-Maksoud, M.A., Salah, M., Zalata, K., *et al.*, 2017. Prediction of Fibrosis Progression Rate in Patients with Chronic Hepatitis C Genotype 4: Role of Cirrhosis Risk Score and Host Factors. *Journal of Interferon & Cytokine Research* 37(3):97-102.
- Bestari, M.B., Nugraha, E.S., Abdurachman, S.A., 2020. The Efficacy of Generic Daclatasvir-Sofosbuvir as Pan-Genotypic Regimen for Hepatitis C Virus (HCV) Infected Patients in Bandung Indonesia. *The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy* 21(1):7-11.
- Carmona, I., Cordero, P., Ampuero, J., Rojas, A., Romero-Gomez M., 2016. Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. *Clinical Microbiology and Infection* 22:839-845.
- Cheng, C.H., Chu, C.Y., Chen, H.L., Lin, I.T., Wu, C.H., Lee, Y.K., *et al.*, 2021. Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers. *Journal of the Formosan Medical Association* 120:1259-1268.

- Costa, L.B., Ferraz, M.L.G., Perez, R.M., Ferreira, A.S., Matos, C.A.L., Lanzoni, V.P., *et al.*, 2002. Effect of Host-Related Factors on the Intensity of Liver Fibrosis in Patients With Chronic Hepatitis C Virus Infection. *The Brazilian Journal of Infectious Diseases* 6(5):219-224.
- Dahlan, S.M. 2013. Besar Sampel dan Cara Pengambilan Sampel, Jakarta : Salemba Medika.
- Ehsan, N., Sweed, D., Elsabaawy, M., 2021. Evaluation of HCV-related liver fibrosis post-successful DAA therapy. *Egyptian Liver Journal* 11:56.
- El-Hariri, M., Megid, A.G., Ali, T.F., Hassany, M., 2017. Diagnostic value of Transient Elastography (*Fibroscan*) in the evaluation of liver fibrosis in chronic viral hepatitis C: Comparison to liver biopsy. *The Egyptian Journal of Radiology and Nuclear Medicine* 48(2):329-337.
- El-Kady, M.S., El-Sahhar, M.H., El-Azab, T.E., Abdel-Rahman, A., Abdel-Azeem, 2021. Effect of DAAs on improvement of liver fibrosis assessed by transient elastography and associated risk factors for accelerating liver fibrosis. *BMFJ* 38(3):972-983.
- Elsharkawy, A., Eleteby, R., Fouad, R., Soliman, Z., Abdallah, M., Negm, M., *et al.*, 2017. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 Patients. *Expert Review of Gastroenterology & Hepatology*, DOI: 10.1080/17474124.2017.1326816.
- Fartoux, L., Poujol-Robert, A., Gue´chot, J., Wendum, D., Poupon, R., Serfaty, L., 2005. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. *Gut* 54:1003-1008.
- Fayed, H.M., Ghweil, A.A., AbdelMeguid, M.M., 2019. Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study. *Interdisciplinary Perspectives on Infectious Diseases*. Article ID 9469567.
- Gani, R.A. *Hepatitis C*. Dalam: *Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi VI*. Jakarta: Interna Publishing; 2014. 1972 – 1977.
- Glässner, A., Eisenhardt, M., Kokordelis, P., Krämer, B., Wolter, F., Nischalke, H.D., *et al.*, 2013. Impaired CD4+ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. *Journal of Hepatology* 59:427-433.
- Gower, E., Estes, C., Blach, S., Razavi-Searer, K., Razavi, H., 2014. Global epidemiology and genotype distribution of hepatitis C virus infection. *Journal of Hepatology* 51:S45-57.

- Hsu, W.F., Lai, H.C., Su, W.P., Lin, C.H., Chuang, P.H., Chen, S.H., *et al.*, 2019. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents. *BMC Gastroenterology* 19:63.
- Hum, J., Jou, J.H., 2018. The Link Between Hepatitis C Virus and Diabetes Mellitus: Improvement in Insulin Resistance After Eradication of Hepatitis C Virus. *Clinical Liver Disease* 11(3):73-76.
- Hyun, J., McMahon, R.S., Lang, A.L., Edwards, J.S., Badilla, A.D., Greene, M.E., *et al.*, 2019. HIV and HCV augments inflammatory responses through increased TREM-1 expression and signaling in Kupffer and Myeloid cells. *PLoS Pathog* 15(7):e1007883.
- Khanam, A., Chua, J.V., Kottlil, S., 2021. Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression. *Int. J. Mol. Sci* 22:5497.
- Khatun, M., Ray, R.B., 2019. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. *Cells* 8:1249.
- Lange, C.M., Jacobson, I.M., Rice, C.M., Zeuzem, S., 2014. Review Series: Host-pathogen interactions, Emerging therapies for the treatment of hepatitis C. *EMBO Molecular Medicine* 6(1):4-15.
- Laursen, T.L., Siggaard, C.B., Konstantin, K., Sandahl, T.D., Møller, H.J., Tarp, B., *et al.*, 2019. Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C. *J Viral Hepat* 00:1-8.
- Lee, S.H., Shin, H.P., Lee J.I., 2020. Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment. *Antiviral Chemistry and Chemotherapy* 0:1-8.
- Lee, Y.C., Hu, T.H., Hung, C.H., Lu, S.N., Chen, C.H., Wang, J.H., 2019. The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals. *PLoS ONE* 14(4):e0214323.
- Leuştean, A., Popescu, C., Nichita, L., Tilişcan, C., Arama, V., 2021. Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy. *Experimental and Therapeutic Medicine* 21(99):1-9.

- Lin, W., Weinberg, E.M., Chung, R.T., 2013. Pathogenesis of Accelerated Fibrosis in HIV/HCV Co-infection. *The Journal of Infectious Diseases* 207 Suppl 1:S13-8.
- Lin, Z.H., Xin, Y.N., Dong, Q.J., *et al.*, 2011. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. *Hepatology* 53:726-36.
- Lledo, G.M., Carrasco, I., Beni'tez-Gutierrez, L.M., Arias, A., Royuela, A., Requena, S., *et al.*, 2018. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. *AIDS* 32:2347–2352.
- Mastroianni, C.M., Lichtner, M., Mascia, C., Zuccalà, P., Vullo, V., 2014. Molecular Mechanisms of Liver Fibrosis in HIV/HCV Coinfection. *International Journal of Molecular Sciences* 15:9184-9208.
- Mendes, L.C., Ferreira, P.A., Miotto, N., Zanaga, L., Gonc,ales, E., Lazarini, M.S., *et al.*, 2016. Transient elastography and APRI score: looking at false positives and false negatives. Diagnostic performance and association to fibrosis staging in chronic hepatitis C. *Brazilian Journal of Medical and Biological Research* 49(9):e5432.
- Mihaila, R., 2018. Liver stiffness in chronic hepatitis C virus infection. *Rom. J. Intern. Med* 0(0):1-26.
- Mihardja, L., Dewi, M., Lestari, C.S.W., Handayani, S., Rofiq, A., Setiawati, V., *et al.* Laporan Riskesdas tahun 2007 bidang biomedis. Jakarta: Kementerian Kesehatan RI, 2012.
- Minme, R., Holzmann, I., Tovo, C.V., Almeida, P.R.L., 2018. Profile of patients with chronic hepatitis C in a public health program in Southern Brazil. *Arq Gastroenterol* 55(4):403-406.
- Pan, C.Q., Gayam, V., Rabinovich, C., Normatov, M., Fidman, B., Wang, D., *et al.*, 2019. Efficacy of Direct-Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States. *The American Geriatrics Society* 00(00):1-9.
- Perhimpunan Peneliti Hati Indonesia. Konsensus Nasional Penatalaksanaan Hepatitis C di Indonesia. Jakarta: Perhimpunan Peneliti Hati Indonesia, 2017.
- Qiu, L.X., Liu, Y.L., Lin, W., Liu, Y.R., Yu, H.B., Wang, X.X., *et al.*, 2021. Liver stiffness measurement is a potent predictor of histological fibrosis regression after hepatitis C virus clearance. *European Journal of Gastroenterology & Hepatology* 33:547-554.

- Ragazzo, T.G., Paranagua-Vezozzo, D., Lima, F.R., Mazo, D.F., Pessoa, M.G., Oliveira, C.P., *et al.*, 2017. Accuracy of transient elastography-FibroScans, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C. *Clinics* 72(9):516-525.
- Reungoat, E., Grigorov, B., Zoulim, F., Pécheur, E.I., 2021. Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis. *Cancers* 13:2270.
- Riset Kesehatan Dasar. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI. Jakarta: Kementerian Kesehatan RI, 2013.
- Rockey, D.C., Friedman, S.L., 2021. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. *Gastroenterology* 160:1502-1520.
- Rungta, S., Kumari, S., Deep, A., Verma, K., Swaroop, S., 2021. APRI and FIB-4 performance to assess liver fibrosis against predefined Fibroscan values in chronic hepatitis C virus infection. *J Family Med Prim Care* 10:4082-8.
- Saif-Al-Islam, M., Mohamed, H.S., Younis, M.A., Abdelhamid, M.Y., Ali, M.M., Khalaf, S., 2020. Impact of Gender Difference on Characteristics and Outcome of Chronic Hepatitis C. *Open Journal of Gastroenterology* 10:281-294.
- Salas-Villalobos, T.B., Lozano-Sepúlveda, S.A., Rincón-Sánchez, A.R., Govea-Salas, M., Rivas-Estilla, A.M., 2017. Mechanisms involved in liver damage resolution after hepatitis C virus clearance. *Medicina Universitaria* 19(75):100-107.
- Salmen, S., Berrueta, L., 2012. Immune Modulators of HIV Infection: The Role of Reactive Oxygen Species. *J Clin Cell Immunol* 3(2):121.
- Saputri, A.M., Magdalení, A. R., Murti, S., 2019. The relationship of APRI score (Aspartate Aminotransferase-to-Platelet Ratio Index) and Pugh Child Score. *Jurnal Ilmu Kesehatan* 7(2):122-129.
- Saragih, R.H., Sismiatuti, R.W. 2020. Tatalaksana Koinfeksi HIV dan Hepatitis C: Fokus pada Direct Acting Antiviral (DAA). *Medika Jurnal Kedokteran Indonesia*.
- Shousha, H.I., Mehassab, M.K., Mehrez, M.I., Afifi, S.A., Elsharkawy, M., Mai Hamed, M., *et al.*, 2017. Non-Invasive Fibrosis Scores and Liver Stiffness Changes in Chronic Hepatitis C after Sofosbuvir-based Treatment. *International Journal of Hepatology & Gastroenterology* 3(4):086-090.


- Singh, A.P., Misra, R., Tandon, R., Ghatak, A., Bhosale, V., Singh, K., 2018. Assessment of Liver Fibrosis by Transient Elastography and APRI (AST to Platelet Ratio) in patients with Chronic Liver Disease. *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)* 17(1):42-47.
- Singh, S., Facciorusso, A., Loomba, R., Falck-Ytter, Y.T., 2018. Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 16:27-38.
- Sokoya, T., Steel, H.C., Nieuwoudt, M., Rossouw, T.M., 2017. HIV as a Cause of Immune Activation and Immunosenescence. *Hindawi Mediators of Inflammation*. Article ID 6825493.
- Soliman, H., Ziada, D., Salama, M., Hamisa, M., Badawi, R., Hawash, N., *et al.*, 2020. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study. *Endocrine, Metabolic & Immune Disorders - Drug Targets* 20:104-111.
- Sulaiman, A. *Hepatitis C*. Dalam: *Buku Ajar Ilmu Penyakit Hati Edisi I Revisi*. Jakarta : CV Sagung Seto; 2012. 223 – 239.
- Tag-Adeen, M., Sabra, A.M., Akazawa, Y., Ohnita, K., 2017. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement. *Hepatic Medicine: Evidence and Research* 9:45-53.
- Tao, Y., Deng, R., Wang, M., Lv, D., Yuan, M., Wang, Y., *et al.*, 2018. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study. *Virology Journal* 15:150.
- Tufan, A.G., Hakim, G.D., Akar, H., Akarsu, M., 2020. Evaluation of fibrosis in chronic hepatitis C patients treated with direct-acting antivirals. *Hepatology Forum* 2:53-58.
- WHO, 2020. Training modules on hepatitis B and C screening, diagnosis and treatment. ISBN 978-92-9022-747-2.
- WHO, 2021. Fact sheets / Detail / Hepatitis C. Available from: URL: [https://www.who.int/news-room/fact-sheets/detail/hepatitis-c#:~:text=Globally%2C%20an%20estimated%2058%20million,carcinoma%20\(primary%20liver%20cancer\).](https://www.who.int/news-room/fact-sheets/detail/hepatitis-c#:~:text=Globally%2C%20an%20estimated%2058%20million,carcinoma%20(primary%20liver%20cancer).)

Yoo, H.W., Park, J.Y., Kim, S.G., Jung, Y.K., Lee, S.H., Kim, M.Y., *et al.*, 2022.
Regression of liver fbrosis and hepatocellular carcinoma development after
HCV eradication with oral antiviral agents. *Scientifc Reports* 12:193.

Zakaria, M.K., Sankhyan, A., Ali, A., Fatima, K., Azhar, E., Qadri, I., 2014.
HBV/HCV Infection and Inflammation. *Journal of Genetic Syndromes &
Gene Therapy* 5(5):1-11.


LAMPIRAN

Lampiran 1. Grafik Hasil Penelitian




Gambar 1. Grafik perubahan median skor APRI dari sebelum terapi dan saat SVR12

*APRI: *Aspartate Aminotransferase-Platelet Ratio Index*




Gambar 2. Grafik perubahan median nilai *transient elastography* dari sebelum terapi dan saat SVR12

*TE: *transient elastography*




Gambar 3. Grafik perubahan median skor APRI sebelum terapi dan saat SVR12, berdasarkan kategori skor APRI sebelum terapi < 1 dan ≥ 1

*APRI: *Aspartate Aminotransferase-Platelet Ratio Index*




Gambar 4. Grafik perubahan median nilai *transient elastography* sebelum terapi dan saat SVR12, berdasarkan kategori nilai *transient elastography* sebelum terapi < 9,6 kPa dan ≥ 9,6 kPa


*TE: *transient elastography*



Gambar 5. Grafik penurunan skor APRI dari sebelum terapi dan saat SVR12, berdasarkan kategori usia




Gambar 6. Grafik penurunan skor APRI dari sebelum terapi dan saat SVR12, berdasarkan kategori jenis kelamin




Gambar 7. Grafik penurunan skor APRI dari sebelum terapi dan saat SVR12, berdasarkan kategori HCV RNA kuantitatif


*VL: viral load



Gambar 8. Grafik penurunan nilai *transient elastography* dari sebelum terapi dan saat SVR12, berdasarkan kategori usia



Gambar 9. Grafik penurunan nilai *transient elastography* dari sebelum terapi dan saat SVR12, berdasarkan kategori jenis kelamin



Gambar 10. Grafik penurunan nilai *transient elastography* dari sebelum terapi dan saat SVR12, berdasarkan kategori HCV RNA kuantitatif

*VL: viral load

Lampiran 2. Lembaran Tes dan Ikhtisar Pengobatan Pasien Hepatitis C

HepC 01








TES DAN IKHTISAR PENGOBATAN PASIEN HEPATITIS C					
1. Identitas Pasien					
NIK : Nama : Tgl Masuk RS : DD / MM / YYYY Nama dokter spesialis : RS : No RM : Jenis Kelamin : L / P Tgl Lahir : DD / MM / YYYY TB : BB : Nama Ibu Kandung : Status pernikahan : Menikah / Belum Menikah / Cerai Pendidikan : Pekerjaan : Alamat : No. telp / HP : Faktor Risiko : Penasun / Hemodialisa / Transfusi darah / LSL / Waria / WPS / Operasi / Lainnya Nama PMO : Hubungan dengan Pasien : Alamat PMO : No. telp / HP PMO :					
2. Riwayat Tes & Pengobatan Sebelumnya					
Pernah Tes Hepatitis C (Anti HCV) : Ya / Tidak Jika Ya, Hasil Tes Terakhir : Positif / Negatif / Tidak diketahui Pernah tes HCV RNA : Ya / Tidak Jika Ya, Pernah Terdeteksi : Ya / Tidak / Tidak diketahui Pernah Pengobatan Hep C : Ya / Tidak Jika Ya, Rejimen yg digunakan : Hasil Pengobatan : L/TL/SVR/Non SVR/Tdk tahu					
3. Diagnosa Hepatitis C					
Tipe tes	Tgl ambil sampel	Jumlah VL	Hasil	Tempat Tes (Pilih Salah Satu)	
Tes anti HCV				RS / RS Lain / PKM / Lab Swasta	
Viral load HCV RNA*				RS / RS Lain / PKM / Lab Swasta	
Tes Genotipe HCV				RS / RS Lain / PKM / Lab Swasta	
4. Pemeriksaan Awal					
Haemoglobin:	Lekosit:	Trombosit:	ALT/SGPT:	AST/SGOT:	SGOT Normal batas atas:
Albumin:	Bilirubin:	INR:	Ureum:	Kreatinin:	
Dasar diagnosis Sirosis (salah satu dari empat tes wajib):					
Nama Tes	Tgl Tes	Nilai KPα	Skor	Keterangan	
Pemeriksaan Klinis / USG				(...) Nodul (...) Fatty Liver Lainnya:.....	
Fibroscan					
APRI					
FIB 4					
Tingkat keparahan hepatitis C : Tidak ada sirosis / Kompensasi sirosis / Dekompensasi sirosis					
Dasar diagnosis dekompensasi Sirosis (bagi pasien sirosis):					
Tgl : DD / MM / YYYY Ensefalopati : +/- Asites : +/- Perdarahan Varises : +/- Skor Child Pugh : A/B/C					
5. Koinfeksi					
Pernah Tes HIV Sebelum Pengobatan : Ya / Tidak Status HIV (jika pernah tes HIV) : Reaktif / Non Reaktif / Tidak diketahui Sudah Mulai ART (jika status HIV reaktif) : Ya / Tidak Rejimen ART (jika sudah ART) : Tgl dianjurkan tes HIV (jika belum pernah tes HIV) : DD / MM / YYYY Hasil tes HIV : Reaktif / Non Reaktif / Tidak diketahui Menderita Hepatitis B : Ya / Tidak Sedang dalam Pengobatan Hepatitis B : Ya / Tidak					
6. Detail Pengobatan					
Tanggal mulai pengobatan : DD / MM / YYYY Lama Pengobatan : <input type="checkbox"/> 12 Minggu <input type="checkbox"/> 24 Minggu <input type="checkbox"/> Lainnya:.....					
Rejimen :					
<input type="checkbox"/> PegIFN (2A/2B) + RBV + SOF <input type="checkbox"/> PegIFN (2A/2B) + RBV + SIM <input type="checkbox"/> SOF + DAC (30/60/90) <input type="checkbox"/> SOF + DAC (30/60/90) + RBV <input type="checkbox"/> SOF + SIM <input type="checkbox"/> SOF + SIM + RBV <input type="checkbox"/> Rejimen Lainnya:.....					
Tgl disarankan kunjungan ke-2 : DD / MM / YYYY					
7. Pemantauan Viral Load					
Tipe tes	Tgl tes disarankan	Tgl tes	Jumlah viral load	Hasil	
Viral load HCV RNA (isikan sesuai dengan nomer 3 di atas)					
Viral load HCV pada 4 minggu pengobatan (pilihan)					
Viral load HCV pada akhir pengobatan (ETR) (pilihan)					
Viral load HCV 12 mgg setelah pengobatan selesai (SVR12)					
8. Hasil Akhir Pengobatan					
Hasil pengobatan : Lengkap (L) / Tidak Lengkap (TL) / SVR / Non SVR Tanggal Hasil pengobatan : DD / MM / YYYY Alasan TL/Non SVR : <input type="checkbox"/> Gagal <input type="checkbox"/> Lost to Follow Up <input type="checkbox"/> Rujuk Keluar <input type="checkbox"/> Meninggal <input type="checkbox"/> Lainnya:.....					

HepC 01





9. Detail Kunjungan

[illegible]

Lampiran 3. Persetujuan Etik

	MEDICAL AND HEALTH RESEARCH ETHICS COMMITTEE (MHREC) FACULTY OF MEDICINE, PUBLIC HEALTH AND NURSING UNIVERSITAS GADJAH MADA – DR. SARDJITO GENERAL HOSPITAL				
ETHICS COMMITTEE APPROVAL					
Ref. No. : KE/FK/0529/EC/2022					
Title of the Research Protocol	: Peran <i>Direct Acting Antiviral</i> Terhadap Perbaikan <i>Liver Stiffness</i> pada Pasien Hepatitis C Kronik di RSUP Dr. Sardjito Yogyakarta				
Document(s) Approved and version	: Study Protocol version 02 2022				
Principle Investigator	: Indria Melianti				
Participating Investigator(s)	: 1. dr. Neneng ratnasari, Sp.PD., KEGH. 2. dr. Fahmi Indrarti, Sp.PD-KGEH.				
Date of Approval	: 28 APR 2022 (Valid for one year beginning from the date of approval)				
Institution(s)/place(s) of research	: Poliklinik Penyakit Dalam RSUP Dr. Sardjito Yogyakarta				
<p>The Medical and Health Research Ethics Committee (MHREC) states that the document above meets the ethical principle outlined in the International and National Guidelines on ethical standards and procedures for researches with human beings.</p> <p>The Medical and Health Research Ethics Committee (MHREC) has the right to monitor the research activities at any time.</p> <p>The investigator(s) is/are obliged to submit:</p> <ul style="list-style-type: none"><input checked="" type="checkbox"/> Progress report as a continuing review (state its due time)<input checked="" type="checkbox"/> Report of any serious adverse events (SAE)<input checked="" type="checkbox"/> Final report upon the completion of the study					
 Prof. Dr. dr. Sri Sutarni, Sp.S(K). Panel's chairperson	 dr. Yunita Widyastuti, Sp.An., M.Kes., KAP., Ph.D. Panel's secretary				
<table border="1" style="width: 100%;"><tr><td style="width: 60%;"><p>P.S: This letter uses signature scan of the panel's chairperson and Secretary of the Ethics Committee. The hardcopy official letter with authority's signature will be issued when it is possible and are kept as an archive of the Ethics Committee</p></td><td style="width: 30%;"><p>Validation number : 6268f7451bf96 (http://komisi Etik.fk.ugm.ac.id/validasi)</p></td><td style="width: 10%;"></td></tr></table>			<p>P.S: This letter uses signature scan of the panel's chairperson and Secretary of the Ethics Committee. The hardcopy official letter with authority's signature will be issued when it is possible and are kept as an archive of the Ethics Committee</p>	<p>Validation number : 6268f7451bf96 (http://komisi Etik.fk.ugm.ac.id/validasi)</p>	
<p>P.S: This letter uses signature scan of the panel's chairperson and Secretary of the Ethics Committee. The hardcopy official letter with authority's signature will be issued when it is possible and are kept as an archive of the Ethics Committee</p>	<p>Validation number : 6268f7451bf96 (http://komisi Etik.fk.ugm.ac.id/validasi)</p>				
<p>Recognized by Forum for Ethical Review Committees in Asia and the Western Pacific (FERCAP) 27-Apr-22</p>					

Lampiran 4. Ijin Penelitian

	KEMENTERIAN KESEHATAN REPUBLIK INDONESIA DIREKTORAT JENDERAL PELAYANAN KESEHATAN RUMAH SAKIT UMUM PUSAT Dr. SARDJITO Jl. Kesehatan No. 1 Sekip Yogyakarta Telepon: +62-274-587333 Faks: +62-274-565639 Email: admin@sardjitohospital.co.id Website: http://www.sardjito.co.id	
Nomor : LB.02.01/XI.2.2/9380/2022		31 Mei 2022
Lampiran : Dua Lembar		
Hal : Ijin Penelitian*an. Indria Meliati, dengan judul "Peran Direct Acting Antiviral Terhadap Perbaikan Liver Stiffness Pada Pasien Hepatitis C Kronik di RSUP Dr. Sardjito Yogyakarta".		
Yth. Ketua Departemen Ilmu Penyakit Dalam Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan Universitas Gadjah Mada		
Menjawab surat saudara, perihal tersebut pada pokok surat, pada prinsipnya kami dapat membantu dan mengijinkan pelaksanaan penelitian atas nama :		
Nama	: Indria Meliati	
NIM	: 19/453581/PKU/18478	
Judul	: "Peran Direct Acting Antiviral Terhadap Perbaikan Liver Stiffness Pada Pasien Hepatitis C Kronik di RSUP Dr. Sardjito Yogyakarta"	
Tempat Penelitian	: Instalasi Rekam Medik, Instalasi Rawat Jalan (Poliklinik Penyakit Dalam Rumah Sakit RSUP Dr. Sardjito	
dengan Ketentuan sebagai berikut :		
1. Mematuhi protokol kesehatan di RSUP Dr. Sardjito		
2. Sesuai prosedur tetap administrasi penelitian di RSUP Dr. Sardjito		
3. Melengkapi <i>Ethics Commite Approval</i> dari Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan Universitas Gadjah Mada		
4. Mencantumkan nama RSUP Dr. Sardjito di dalam naskah hasil penelitian		
5. Menyerahkan hasil penelitian kepada RSUP Dr. Sardjito (Bagian Pendidikan dan Penelitian berupa CD, Instalasi Perpustakaan dan Instalasi terkait.		
Untuk kelancaran penelitian tersebut agar menghubungi Bagian Pendidikan & Penelitian RSUP Dr. Sardjito, di pesawat (0274) 518669 pada hari dan jam kerja.		
Atas perhatian dan kerja sama yang baik diucapkan terima kasih.		
Direktur Sumber Daya Manusia, Pendidikan, dan Penelitian,		
		
drg. Nusati Ikawahju, M.Kes. NIP 196812071994032003		
	Dokumen ini telah ditandatangani secara elektronik menggunakan sertifikat elektronik yang diterbitkan oleh BSRfE	

Tembusan :

1. Ka. Instalasi Rawat Jalan (Poliklinik Penyakit Dalam)
2. Ka. Instalasi Rekam Medik
3. Yang Bersangkutan